아카시아 식이섬유
Acacia Fiber (Prebiotic)
📚 관련 논문 (17편)
1. Clin Nutr ESPEN. 2025 Feb;65:408-417. doi: 10.1016/j.clnesp.2024.12.016. Epub 2024 Dec 20. Behavioural, cognitive, and neurophysiological effects of a synbiotic supplementation enriched with pigmented corn extract or cornstarch in drug-naïve children with attention-deficit hyperactivity disor
2. Eur J Nutr. 2024 Aug;63(5):1983-1994. doi: 10.1007/s00394-024-03398-8. Epub 2024 Apr 23. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Janss
3. Nutr Metab Cardiovasc Dis. 2024 Jun;34(6):1416-1426. doi: 10.1016/j.numecd.2024.01.028. Epub 2024 Feb 6. Impact of fibre supplementation on microbiome and resilience in healthy participants: A randomized, placebo-controlled clinical trial. Eveleens Maarse BC(1), Eggink HM(2), Warnke I(3), Bij
4. J Nutr. 2022 Apr 1;152(4):1015-1021. doi: 10.1093/jn/nxac003. Prebiotic Galacto-Oligosaccharides and Fructo-Oligosaccharides, but Not Acacia Gum, Increase Iron Absorption from a Single High-Dose Ferrous Fumarate Supplement in Iron-Depleted Women. Giorgetti A(1), Husmann FMD(1), Zeder C(1), He
1. Clin Nutr ESPEN. 2026 Apr;72:102896. doi: 10.1016/j.clnesp.2025.102896. Epub 2026 Jan 10. Fibre manipulation to manage symptom severity and quality of life in patients with functional bowel disorders: A systematic review. Raked R(1), Ibrahim M(2), Utter J(3), Morley S(4), Mueller K(5). Author information: (1)Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina QLD 4226, Australia. Electronic address: rojina.raked@gmail.com. (2)Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina QLD 4226, Australia. Electronic address: mary.ibrahim@student.bond.edu.au. (3)Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina QLD 4226, Australia; Mater Health, Raymond Terrace, South Brisbane QLD 4101, Australia. Electronic address: jutter@bond.edu.au. (4)Mater Health, Raymond Terrace, South Brisbane QLD 4101, Australia. Electronic address: shannon.morley@mater.org.au. (5)Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina QLD 4226, Australia. Electronic address: kmueller@bond.edu.au. BACKGROUND & AIMS: Functional Bowel Disorders (FBD) are clinically diagnosable conditions impacting the mid to lower gastrointestinal tract. Fibre manipulation (through amount or type) is commonly employed as a first-line treatment for symptom management. This systematic review will investigate the impact of fibre manipulation on symptom management and quality of life in adults diagnosed with FBD. METHODS: Four electronic databases (PubMed, EMBASE, CINAHL, and Cochrane Central) were systematically searched from January 2013 to December 2024. Studies were included if they reported Randomised Controlled Trials (RCTs) examining the impact of fibre manipulation in adults (≥18 years) with FBD. The primary outcome was symptom management, and secondary outcome was Quality of Life (QoL). Study quality was assessed using the Cochrane risk of bias tool 2. Data were narratively synthesised. RESULTS: Searches identified 8864 records; 5167 were screened against the eligibility criteria, and 44 records were assessed at full-text review. Ten studies reporting eight parallel and two crossover RCTs evaluating differing fibre supplements and doses for people with various types of FBD were included. Intervention length ranged from one to eight weeks, and the number of participants ranged from 11 to 250. The reported results varied. Seven studies reported significant improvements in symptom severity, and one study reported significant worsening of symptoms when compared to controls. The results indicated that fibre supplementation with agave fructans improved constipation but worsened flatulence, acacia fibre improved stool frequency, psyllium improved stool consistency, nopal fibre improved symptom severity, vege-powder improved stool hardness and amount, incomplete evacuation, straining and evacuation frequency, pectin powder improved abdominal pain, bloating, stool consistency and symptom severity, and a combination of sugarcane bagasse and resistant starch improved flatulence. One study reported significant worsening in QoL in the intervention group when compared to the placebo control group. CONCLUSIONS: This review concluded that fibre supplementation may be an effective treatment to improve symptom management for patients with FBD, though high heterogeneity precluded meta-analysis. Two studies were assessed as low risk of bias, seven had some concerns, and one was assessed as high risk of bias. The included studies reported short-term interventions for small groups of participants. Further research with greater numbers of participants with FBD that evaluate interventions for longer time periods are warranted. Copyright © 2026 The Author(s). Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.clnesp.2025.102896 PMID: 41525871 [Indexed for MEDLINE] Conflict of interest statement: Conflict of interest There was no conflict of interest between the authors or any third parties during the development of this review.
2. Front Nutr. 2021 Mar 10;8:552049. doi: 10.3389/fnut.2021.552049. eCollection 2021. Dietary Fibers (Gum Arabic) Supplementation Modulates Hepatic and Renal Profile Among Rheumatoid Arthritis Patients, Phase II Trial. Kamal E(1), Kaddam LA(2), Alagib A(3), Saeed A(4). Author information: (1)Department of Microbiology and Immunology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. (2)Department of Physiology, Faculty of Medicine, Alneelain University, Khartoum, Sudan. (3)Department of Rheumatology, Military Hospital, Khartoum, Sudan. (4)Department of Physiology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. Background: Rheumatoid arthritis (RA) is an autoimmune disease that mainly affects the synovial joints with systemic manifestations. RA has a major impact on liver and kidney functions as part of the disease pathogenesis or as a sequel of disease medications or, mostly, both of them. The kidney and liver involvement increases the RA morbidity and mortality. Nowadays, dietary interventions are proposed as potential modifiers for disease severity. Gum Arabic (GA) is acacia senegal exudates; it is soluble fiber with prebiotic properties. GA has been discovered to be protective against experimental nephrotoxicity and hepatotoxicity, with comparable findings in human studies. This article addresses the effect of GA on hepatic and renal profile among RA patients. Methods: Forty patients aged 18-70 received GA daily for 12 weeks as a single dose of 30 g. The liver enzymes, total protein level, serum albumin, serum globulin level, urea, creatinine, and serum electrolytes have been measured as a baseline after 4 weeks and by the end of the study. Cobas C311 (Roche, Germany) automated chemistry analyzer directly determined the values for total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and creatinine. The study ethically has been approved by the Ethical Committee of the National Medicines and Poisons Board. Trial Registration Identifier: NCT02804581. Results: Regarding the liver enzymes, GA has significantly decreased the liver enzymes apart from alkaline phosphatase, which showed no significant change. In contrast, GA has increased the serum albumin level with a minor impact on the serum globulin level. Furthermore, GA has also significantly decreased the level of urea (P = 0.0001) and level of Sodium (P = 0.002) with nonsignificant change on creatinine and potassium concentrations. Conclusion: GA presents hepatic and renal protective effects among RA patients, evidenced by the significant reduction of urea and liver enzymes. Thus, it can be recommended as a dietary supplement for RA patients. Nonetheless, we recommend further investigation to support our findings. Copyright © 2021 Kamal, Kaddam, Alagib and Saeed. DOI: 10.3389/fnut.2021.552049 PMCID: PMC7987669 PMID: 33777988 Conflict of interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
3. World J Gastroenterol. 2012 Sep 7;18(33):4563-9. doi: 10.3748/wjg.v18.i33.4563. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. Min YW(1), Park SU, Jang YS, Kim YH, Rhee PL, Ko SH, Joo N, Kim SI, Kim CH, Chang DK. Author information: (1)Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea. AIM: To investigate whether composite yogurt with acacia dietary fiber and Bifidobacterium lactis (B. lactis) has additive effects in irritable bowel syndrome (IBS). METHODS: A total of 130 patients were randomly allocated to consume, twice daily for 8 wk, either the composite yogurt or the control product. The composite yogurt contained acacia dietary fiber and high-dose B. lactis together with two classic yogurt starter cultures. Patients were evaluated using the visual analog scale via a structured questionnaire administered at baseline and after treatment. RESULTS: Improvements in bowel habit satisfaction and overall IBS symptoms from baseline were significantly higher in the test group than in the control group (27.16 vs 15.51, P = 0.010, 64.2 ± 17.0 vs 50.4 ± 20.5, P < 0.001; respectively). In constipation-predominant IBS, improvement in overall IBS symptoms was significantly higher in the test group than in the control group (72.4 ± 18.4 vs 50.0 ± 21.8, P < 0.001). In patients with diarrhea-predominant IBS, improvement in bowel habit satisfaction from baseline was significantly higher in the test group than in the control group (32.90 vs 7.81, P = 0.006). CONCLUSION: Our data suggest that composite yogurt enriched with acacia fiber and B. lactis has greater therapeutic effects in patients with IBS than standard yogurt. DOI: 10.3748/wjg.v18.i33.4563 PMCID: PMC3435782 PMID: 22969230 [Indexed for MEDLINE]
4. Meat Sci. 2010 Apr;84(4):621-7. doi: 10.1016/j.meatsci.2009.10.021. Epub 2009 Oct 31. Meat quality of Nguni steers supplemented with Acacia karroo leaf-meal. Mapiye C(1), Chimonyo M, Dzama K, Muchenje V, Strydom PE. Author information: (1)Department of Livestock and Pasture Science, University of Fort Hare, Private Bag X1314, Alice 5700, South Africa. The objective of the study was to determine the meat quality of Nguni steers supplemented with Acacia karroo leaf-meal. Thirty 19-month old steers were randomly assigned to A. karroo leaf-meal (AK), sunflower cake (SF) and a control (CN) diets. Steers on the AK and SF diets were given an additional 150 g of protein per day for 60 days. The steers were slaughtered at 21 months and the m.longissimus thoracis et lumborum was sampled for meat quality measurements. Steers that received SF diet had lighter-coloured (L*) (P<0.05) meat than those on AK and CN diets. The highest redness (a*) (17.3+/-0.29) values were recorded in steers supplemented with AK compared to those that received SF and CN diets. Diet had no effect on pH, drip loss, water holding capacity, sarcomere length, muscle bundle areas, myofibrillar fragment length, Warner-Bratzler shear force and cholesterol values. Steers supplemented with AK (22.4+/-0.08%) and SF (22.5+/-0.08%) had higher (P<0.05) meat protein content than those on the CN (20.2+/-0.08%) diet. Highest muscle fibre area (3472.6+/-119.51 microm(2)), fat content (1.2+/-0.11%) and cooking loss (25.2+/-0.73%) of meat aged for 2 days were recorded in steers given the SF diet compared to those on the AK and CN diets. Supplementing Nguni cattle with A. karroo leaf-meal produced beef of comparable quality to natural pasture alone but with a fresher appearance and higher protein content. 2009 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.meatsci.2009.10.021 PMID: 20374833 [Indexed for MEDLINE]
5. medRxiv [Preprint]. 2025 Nov 21:2025.11.20.25340625. doi: 10.1101/2025.11.20.25340625. Mechanistic insights into microbiome-dependent and personalized responses to dietary fibre in a randomized controlled trial. Armet AM(1)(2)(3), Li F(4)(1)(3), Deehan EC(1)(5)(6), Nikolaeva DD(7)(8), Delannoy-Bruno O(9), Siegwald L(9), Berger B(9), Castelli KM(9), Rodionov DA(10), Arzamasov AA(10), Liu J(1), Seethaler B(11), Cole JL(1), Nguyen KN(1), Jin M(1), Zhao YY(1), Sharma AM(1), Curtis JM(1), Proctor SD(1), Bischoff SC(11), Wismer WV(1), Osterman AL(10), Bakal JA(12), Greiner R(13)(14), Field CJ(1), Knights D(15)(16), Prado CM(1), Walter J(1)(7)(17)(18)(19)(20). Author information: (1)Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, Canada. (2)Department of Pediatrics, University of Alberta, Edmonton, Canada. (3)These authors contributed equally. (4)Department of Animal Science and Technology, College of Animal Sciences, Zhejiang University, Hangzhou, China. (5)Department of Food Science and Technology, University of Nebraska, Lincoln, USA. (6)Nebraska Food for Health Center, University of Nebraska, Lincoln, USA. (7)APC Microbiome Ireland, University College Cork, Cork, Ireland. (8)Center for Molecular and Cellular Biology, Skolkovo Institute of Science and Technology, Moscow, Russia. (9)Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé S.A., 1000 Lausanne, Switzerland. (10)Center for Data Sciences, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA. (11)Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany. (12)Patient Health Outcomes Research and Clinical Effectiveness Unit, Division of General Internal Medicine, University of Alberta, Edmonton, Canada. (13)Department of Computing Science, University of Alberta, Edmonton, Canada. (14)Alberta Machine Intelligence Institute, Edmonton, Canada. (15)Department of Computer Science and Engineering, University of Minnesota, Minneapolis, USA. (16)Biotechnology Institute, University of Minnesota, Saint Paul, USA. (17)School of Microbiology, University College Cork, Cork, Ireland. (18)Department of Medicine, University College Cork, Cork, Ireland. (19)Department of Biological Sciences, University of Alberta, Edmonton, Canada. (20)Lead contact. Dietary fiber supplementation can reduce cardiometabolic risk, but its effective use is limited by incomplete understanding of fibre-microbiome interactions and highly individualized responses. We tested acacia gum (AG; fermentable fibre), resistant starch type 4 (RS4; fermentable fibre), and microcrystalline cellulose (MCC; non-fermentable control fibre) in a six-week randomized trial in adults with excess body weight. Multi-omics profiling revealed distinct, structure-specific microbiota and short-chain fatty acid shifts with AG and RS4, which were not directly linked to physiological outcomes. Improvements in inflammation, gut barrier function, and satiety occurred across all arms, indicating fermentation-independent effects. AG reduced plasma ghrelin, linked to microbial carbohydrate-active enzyme genes targeting its structures. Machine-learning models predicted individualized, fiber-specific effects on blood pressure (AG) and C-reactive protein (RS4) from microbial pathways and fecal bile acids. These findings delineate fermentation-dependent and independent mechanisms of fibre action and provide a mechanistic basis for personalized fibre supplementation. TRIAL REGISTRATION: ClinicalTrials.gov NCT02322112. DOI: 10.1101/2025.11.20.25340625 PMCID: PMC12668032 PMID: 41332831 Conflict of interest statement: A.M.A. completed a paid internship with Société des Produits Nestlé S.A. to receive training in microbiome data analysis. E.C.D. has received paid consultancy from Comet Bio unrelated to this work. O.D.B., L.S., B.B., and K.M.C. are employees of Société des Produits Nestlé S.A.. A.L.O. and D.A.R. are cofounders of Phenobiome Inc., a company pursuing the development of computational tools for predictive phenotype profiling of microbial communities. C.M.P. has previously received honoraria and/or paid consultancy from Abbott Nutrition, Nutricia, Nestlé Health Science, and Novo Nordisk unrelated to this work. J.W. is a founder and co-owner of Synbiotic Health and declares support and consultancy from MGP Ingredients and Nestlé as relevant to this manuscript. All other authors declare no competing interests.
6. Nephrol Dial Transplant. 2024 Sep 27;39(10):1649-1661. doi: 10.1093/ndt/gfae053. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Zhuang B(1), Gan L(2), Liu B(3), Yuan W(4), Shi M(5), Peng A(6), Wang L(7), Chen X(8), Liu T(9), Zhang S(10), Wang S(11), Gao Q(12), Wang B(13), Zheng H(14), Liu C(15), Luo Y(1), Ye H(1), Lin H(16), Li Y(17), He Q(17), Zheng F(18), Luo P(19), Long G(20), Lu W(21), Li K(22), Yang J(1), Liu YC(23), Zhang Z(23), Li X(23), Zhang W(23), Zuo L(2). Author information: (1)Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, China. (2)Department of Nephrology, Peking University People's Hospital, Beijing, China. (3)Nephrology Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China. (4)Nephrology Department, Shanghai General Hospital, Shanghai, China. (5)Nephrology Department, Renmin Hospital of Wuhan University, Wuhan, China. (6)Nephrology Department, Shanghai Tenth Hospital, Shanghai, China. (7)Nephrology Department, The Second Hospital of Shanxi Medical University, Taiyuan, China. (8)Nephrology Department, Affiliated Hospital of Nantong University, Nantong, China. (9)Nephrology Department, Changzhou No. 2 People's Hospital, Changzhou, China. (10)Nephrology Department, Jilin Province People's Hospital, Changchun, China. (11)Nephrology Department, Peking University Third Hospital, Beijing, China. (12)Department of Nephrology, Zhongshan Hospital of Xiamen University School of Medicine, Xiamen, China. (13)Nephrology Department, The Third Hospital of Hebei Medical University, Shijiazhuang, China. (14)Nephrology Department, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, China. (15)Nephrology Department, Northern Jiangsu People's Hospital, Yangzhou, China. (16)Nephrology Department, The First Hospital of Dalian Medical University, Dalian, China. (17)Department of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, China. (18)Nephrology Department, The Second Hospital of Dalian Medical University, Dalian, China. (19)Nephrology Department, The Second Hospital of Jilin University, Changchun, China. (20)Department of Nephrology, Tianjin Union Medical Center, Tianjin, China. (21)Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. (22)Nephrology Department, The Affiliated Hospital of Guilin Medical University, Guilin, China. (23)Shanghai Alebund Pharmaceuticals Limited, Shanghai, China. BACKGROUND: VS-505 (AP301), an acacia and ferric oxyhydroxide polymer, is a novel fiber-iron-based phosphate binder. This two-part Phase 2 study evaluated the tolerability, safety and efficacy of oral VS-505 administered three times daily with meals in treating hyperphosphatemia in chronic kidney disease (CKD) patients receiving maintenance hemodialysis (MHD). METHODS: In Part 1, patients received dose-escalated treatment with VS-505 2.25, 4.50 and 9.00 g/day for 2 weeks each, guided by serum phosphorus levels. In Part 2, patients received randomized, open-label, fixed-dosage treatment with VS-505 (1.50, 2.25, 4.50 or 6.75 g/day) or sevelamer carbonate 4.80 g/day for 6 weeks. The primary efficacy endpoint was the change in serum phosphorus. RESULTS: The study enrolled 158 patients (Part 1: 25; Part 2: 133), with 130 exposed to VS-505 in total. VS-505 was well tolerated. The most common adverse events were gastrointestinal disorders, mainly feces discolored (56%) and diarrhea (15%; generally during Weeks 1-2 of treatment). Most gastrointestinal disorders resolved without intervention, and none was serious. In Part 1, serum phosphorus significantly improved (mean change -2.0 mg/dL; 95% confidence interval -2.7, -1.4) after VS-505 dose escalation. In Part 2, serum phosphorus significantly and dose-dependently improved in all VS-505 arms, with clinically meaningful reductions with VS-505 4.50 and 6.75 g/day, and sevelamer carbonate 4.80 g/day [mean change -1.6 (-2.2, -1.0), -1.8 (-2.4, -1.2) and -1.4 (-2.2, -0.5) mg/dL, respectively]. In both parts, serum phosphorus reductions occurred within 1 week of VS-505 initiation, returning to baseline within 2 weeks of VS-505 discontinuation. CONCLUSION: VS-505, a novel phosphate binder, was well tolerated with a manageable safety profile, and effectively and dose-dependently reduced serum phosphorus in CKD patients with hyperphosphatemia receiving MHD. CLINICAL TRIAL REGISTRATION NUMBER: NCT04551300 . © The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. DOI: 10.1093/ndt/gfae053 PMID: 38453435 [Indexed for MEDLINE]
7. Nutrients. 2021 Feb 14;13(2):618. doi: 10.3390/nu13020618. Acacia Gum Is Well Tolerated While Increasing Satiety and Lowering Peak Blood Glucose Response in Healthy Human Subjects. Larson R(1), Nelson C(1), Korczak R(1), Willis H(1), Erickson J(1), Wang Q(2), Slavin J(1). Author information: (1)Food Science and Nutrition Department, University of Minnesota, 1334 Eckles Ave, Falcon Heights, MN 55108, USA. (2)Clinical and Translational Science Institute, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414, USA. Acacia gum (AG) is a non-viscous soluble fiber that is easily incorporated into beverages and foods. To determine its physiological effects in healthy human subjects, we fed 0, 20, and 40 g of acacia gum in orange juice along with a bagel and cream cheese after a 12 h fast and compared satiety, glycemic response, gastrointestinal tolerance, and food intake among treatments. Subjects (n = 48) reported less hunger and greater fullness at 15 min (p = 0.019 and 0.003, respectively) and 240 min (p = 0.036 and 0.05, respectively) after breakfast with the 40 g fiber treatment. They also reported being more satisfied at 15 min (p = 0.011) and less hungry with the 40 g fiber treatment at 30 min (p = 0.012). Subjects reported more bloating, flatulence, and GI rumbling on the 40 g fiber treatment compared to control, although values for GI tolerance were all low with AG treatment. No significant differences were found in area under the curve (AUC) or change from baseline for blood glucose response, although actual blood glucose with 20 g fiber at 30 min was significantly less than control. Individuals varied greatly in their postprandial glucose response to all treatments. AG improves satiety response and may lower peak glucose response at certain timepoints, and it is well tolerated in healthy human subjects. AG can be added to beverages and foods in doses that can help meet fiber recommendations. DOI: 10.3390/nu13020618 PMCID: PMC7918852 PMID: 33672963 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
8. Nutrients. 2021 Jan 9;13(1):194. doi: 10.3390/nu13010194. The Effect of Gum Arabic (Acacia Senegal) on Cardiovascular Risk Factors and Gastrointestinal Symptoms in Adults at Risk of Metabolic Syndrome: A Randomized Clinical Trial. Jarrar AH(1), Stojanovska L(1)(2), Apostolopoulos V(2), Feehan J(2)(3), Bataineh MF(4), Ismail LC(5)(6), Al Dhaheri AS(1). Author information: (1)Nutrition and Health Department, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, UAE. (2)Institute for Health and Sport, Victoria University, Melbourne 3011, Australia. (3)Department of Medicine-Western Health, The University of Melbourne, Melbourne 3010, Australia. (4)Department of Sport and Rehabilitation, The Hashemite University, 13115 Zarqa, Jordan. (5)Clinical Nutrition and Dietetics Department, College of Health Sciences, University of Sharjah, Sharjah 27272, UAE. (6)Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX1 2JD, UK. Gum Arabic (GA) is a widely-used additive in food processing, but is also historically used in a number of traditional therapies. It has been shown to have a broad range of health benefits, particularly in improving important cardiovascular risk indicators. Metabolic syndrome and its associated cardiac outcomes are a significant burden on modern healthcare systems, and complementary interventions to aid in its management are required. We aimed to examine the effect of GA on those with, or at risk of, metabolic syndrome to identify an effect on improving important disease parameters related to cardiovascular outcomes. A single-blind, randomized, placebo-controlled trial was conducted to identify the effects of daily GA supplementation on metabolic and cardiovascular risk factors. A total of 80 participants were randomized to receive 20 g of GA daily (n = 40) or placebo (1 g pectin, n = 40) for 12 weeks. Key endpoints included body-anthropometric indices, diet and physical activity assessment, and blood chemistry (HbA1c, fasting glucose, and blood lipids). Of the 80 enrolled, 61 completed the study (intervention: 31, control: 30) with 19 dropping out due to poor treatment compliance. After 12 weeks, the participants receiving the GA showed significant decreases in systolic and diastolic blood pressure, fat-free body mass, energy and carbohydrate consumption, and fasting plasma glucose, as well as increased intake of dietary fiber. They also reported improvements in self-perceived bloating and quality of bowel movements, as well as a decreased appetite score following GA consumption. These results suggest that GA could be a safe and beneficial adjunct to other treatments for those with, or at risk of, metabolic syndrome. DOI: 10.3390/nu13010194 PMCID: PMC7826716 PMID: 33435475 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.
9. J Anim Physiol Anim Nutr (Berl). 2020 Jan;104(1):101-108. doi: 10.1111/jpn.13261. Epub 2019 Dec 4. Effect of complete feed block with tree leaves rich in hydrolysable and condensed tannins on nutrient utilization, rumen fermentation and growth performance of lambs. Aderao GN(1), Sahoo A(1), Kumawat PK(1), Bhatt RS(1). Author information: (1)Division of Animal Nutrition, ICAR-Central Sheep and Wool Research Institute, Avikanagar, Rajasthan, India. Thirty lambs (Avishaan genotype, 10 weeks old, 14.0 ± 0.2 kg live weight) were randomly assigned into three equal treatment groups to study the effect of complete feed blocks (CFB; concentrate and roughage at 70:30 ratio) with three different tanniniferous tree leaves on intake and utilization of nutrients, rumen fermentation, microbial protein synthesis and growth performance. The treatments were T1 (Control), CFB1 with Vigna sinensis hay; T2, CFB2 with Acacia nilotica leaves rich in hydrolysable tannins (HT); and T3, CFB3 with Ziziphus nummularia leaves rich in condensed tannins (CT). The three CFBs were fed ad libitum to the respective groups of lambs for a period of 12 weeks. There was lower (p < .05) intake of dry matter (DM), total carbohydrates (TCHO) and fibre components in T2 compared with T1 and T3. However, the digestibility of nutrients except crude protein (CP) was higher in T2. Diet had no effect (p > .05) on the LW gain in lambs. Amongst the three groups, T3 showed enhanced N utilization with a comparable microbial protein synthesis, the lowest being in T2. The T2 group of lambs had higher propionate and lower non-glucogenic: glucogenic short-chain fatty acids ratio. It may be concluded that tanniniferous tree leaves at 30% of total mixed ration can meet the requirement of nutrients for desired post-weaning growth. © 2019 Blackwell Verlag GmbH. DOI: 10.1111/jpn.13261 PMID: 31802555 [Indexed for MEDLINE]
10. Lipids Health Dis. 2018 Mar 20;17(1):56. doi: 10.1186/s12944-018-0711-y. Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial. Babiker R(1), Elmusharaf K(2), Keogh MB(3), Saeed AM(4). Author information: (1)Department of Physiology, Faculty of Medicine, University of Medical Sciences & Technology, Khartoum, Sudan. rashat33@yahoo.com. (2)Graduate Entry Medical School, University of Limerick, Limerick, Ireland. (3)Human Biology & Research Laboratory Manager, School of Medicine, Royal College of Surgeons in Ireland RCSI-Bahrain, P.O Box 15503, Adliya, Manama, Bahrain. (4)Department of Physiology, Faculty of Medicine, University of Khartoum, P.O Box 102, Khartoum, Sudan. BACKGROUND: There is a strong association between cardiometabolic risk and adipose tissue dysfunction with great consequences on type 2 diabetic patients. Visceral Adiposity Index (VAI) is an indirect clinical marker of adipose tissue dysfunction. Gum Arabic (GA) is a safe dietary fiber, an exudate of Acacia Senegal. Gum Arabic had shown lipid lowering effect in both humans and animals. The aim of this trial was to determine the effect of GA supplementation on anthropometric obesity marker, Visceral Adiposity Index (VAI) and blood pressure in patients with type 2 diabetes mellitus. METHODS: This randomized, double blinded, placebo controlled trial recruited a total of 91 type 2 diabetic patients (73 females, 18 males), age (mean ± SD) 50.09 ± 9.3 years on hypoglycemic agents and were randomly assigned into two groups, either to consume 30 g of GA or 5 g of placebo daily for 3 months. Anthropometric obesity markers were measured and indices were calculated. Blood pressure was measured and high density lipoprotein (HDL) and triglycerides (TG) were determined in fasting blood samples at the start and end of the study period. RESULTS: After intervention, Gum Arabic decreased BMI and VAI significantly (P < 0.05) in GA group by 2 and 23.7% respectively. Body adiposity index significantly decreased by 3.9% in GA group while there were no significant changes in waist circumference or waist-to-hip ratio (WHR). Systolic blood pressure significantly decreased by 7.6% in GA group and by 2.7% in placebo group from baseline with no significant changes in diastolic blood pressure in the two groups. CONCLUSION: Gum Arabic consumption at a dose of 30 g/d for 3 months may play an effective role in preventing weight gain and modulating adipose tissue dysfunction in type 2 diabetic patients, although no effect has been shown in waist-to-hip ratio. TRIAL REGISTRATION: The trial had been registered as prospective interventional clinical trials in the Pan African Clinical Trial Registry (PACTR) PACTR201403000785219 , on 7th March 2014. DOI: 10.1186/s12944-018-0711-y PMCID: PMC5859434 PMID: 29558953 [Indexed for MEDLINE] Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The trial is in accordance with the Declaration of Helsinki and guidelines from the Sudanese State of Khartoum Ministry of Health Ethical Committee. Approval was obtained by local research ethics committee ‘Institutional Review Board at University of Medical Science and Technology (UMST); SUM 116 -IRB number: 00008867’ .The study was carried out and informed written consent was obtained from all patients before their enrolment. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that there are no competing interests regarding the publication of this paper. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
11. Ostomy Wound Manage. 2014 Oct;60(10):26-33. A systematic review and meta-analysis of randomized controlled trials comparing interventions for peristomal skin care. Tam KW(1), Lai JH(2), Chen HC(3), Hou WH(4), Ko WS(5), Chen SL(5), Huang TW(6). Author information: (1)Taipei Medical University, Taipei, Taiwan; and Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan. (2)HungKuang University, Taichung City, Taiwan and Erlin Branch of Changhua Christian Hospital, Changhua City, Taiwan. (3)Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan. (4)Taipei Medical University, Taipei, Taiwan. (5)HungKuang University, Taichung City, Taiwan. (6)HungKuang University, Taichung City, Taiwan; email:email: m8706001@gmail.com. Standard skin care procedures for percutaneous endoscopic gastrostomy (PEG) tubes and peristomal skin care for colostomy and ileostomy patients are not always sufficient to prevent peristomal skin problems. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to compare the effectiveness of standard peristomal skin care to adjunctive techniques or barriers (including glycogel dressings, gelatin- and pectin-based skin barriers, glycerin hydrogel wound dressing, Acacia senegal fiber pockets, hydrocolloid powder crusting, and German chamomile) to manage or treat patients with a stoma. Using systematic literature search techniques, all healthcare databases were searched up through September 2014. No language restrictions were applied. Studies were included if they met criteria for published RCTs or quasi-RCTs that evaluated the outcome of standardized peristomal skin care and other adjunctive techniques or barriers used among patients with a stoma or PEG tube. A meta-analysis was performed to calculate a pooled effect size by using random-effect models for the primary (skin irritation/reaction) and secondary (length of pouch wear time) outcomes. Six RCTs comprising 418 total patients were identified. Four evaluated the outcome of colostomy or ileostomy peristomal skin care, and no significant differences were detected in the incidence of skin problems (RR 0.67; 95% CI: 0.31-1.41). In the two studies that included length of pouch wear time, no significant differences were observed (RR 0.48; 95% CI: 0.03-7.97). No significant differences were seen in the rate of skin irritations of gastrostomy patients (RR 0.56; 95% CI: 0.20-1.59), but the difference in treatment outcomes of peristomal damage in patients with a colostomy was significant (P = 0.01). The limited number of studies, study quality, heterogeneity of variability in peristomal care strategies and techniques, clinical factors, and nonuniform reporting of clinical parameters contributed to the heterogeneity among the trials. Well-designed RCTs are needed to investigate the efficacy of various barriers and techniques for peristomal skin care and to help develop evidence-based standards of caring for the skin of patients with a colostomy, ileostomy, or gastrostomy. PMID: 25299815 [Indexed for MEDLINE]
12. Nutr J. 2012 Dec 15;11:111. doi: 10.1186/1475-2891-11-111. Effects of Gum Arabic ingestion on body mass index and body fat percentage in healthy adult females: two-arm randomized, placebo controlled, double-blind trial. Babiker R(1), Merghani TH, Elmusharaf K, Badi RM, Lang F, Saeed AM. Author information: (1)Department of Physiology, University of Medical Sciences & Technology, Khartoum, Sudan. rashat33@yahoo.com BACKGROUND: Gum Arabic (acacia Senegal) is a complex polysaccharide indigestible to both humans and animals. It has been considered as a safe dietary fiber by the United States, Food and Drug Administration (FDA) since the 1970s. Although its effects were extensively studied in animals, there is paucity of data regarding its quantified use in humans. This study was conducted to determine effects of regular Gum Arabic (GA) ingestion on body mass index and body fat percentage among healthy adult females. METHODS: A two-arm randomized, placebo controlled, double-blind trial was conducted in the Department of Physiology at the Khartoum University. A total of 120 healthy females completed the study. They were divided to two groups: A test group of 60 volunteers receiving GA (30 gm /day) for 6 weeks and a placebo group of 60 volunteers receiving pectin (1 gm/day) for the same period of time. Weight and height were measured before and after intervention using standardized height and weight scales. Skin fold thickness was measured using Harpenden Skin fold caliper. Fat percentage was calculated using Jackson and Pollock 7 caliper method and Siri equation. RESULTS: Pre and post analysis among the study group showed significant reduction in BMI by 0.32 (95% CI: 0.17 to 0.47; P<0.0001) and body fat percentage by 2.18% (95% CI: 1.54 to 2.83; P<0.0001) following regular intake of 30 gm /day Gum Arabic for six weeks. Side effects caused by GA ingestion were experienced only in the first week. They included unfavorable viscous sensation in the mouth, early morning nausea, mild diarrhea and bloating abdomen. CONCLUSIONS: GA ingestion causes significant reduction in BMI and body fat percentage among healthy adult females. The effect could be exploited in the treatment of obesity. DOI: 10.1186/1475-2891-11-111 PMCID: PMC3570285 PMID: 23241359 [Indexed for MEDLINE]
13. J Pediatr. 2012 Oct;161(4):710-5.e1. doi: 10.1016/j.jpeds.2012.04.043. Epub 2012 Jun 5. A randomized, prospective, comparison study of a mixture of acacia fiber, psyllium fiber, and fructose vs polyethylene glycol 3350 with electrolytes for the treatment of chronic functional constipation in childhood. Quitadamo P(1), Coccorullo P, Giannetti E, Romano C, Chiaro A, Campanozzi A, Poli E, Cucchiara S, Di Nardo G, Staiano A. Author information: (1)Department of Pediatrics, University "Federico II," Naples, Italy. Erratum in J Pediatr. 2012 Dec;161(6):1180. OBJECTIVES: To compare the effectiveness of a mixture of acacia fiber, psyllium fiber, and fructose (AFPFF) with polyethylene glycol 3350 combined with electrolytes (PEG+E) in the treatment of children with chronic functional constipation (CFC); and to evaluate the safety and effectiveness of AFPFF in the treatment of children with CFC. STUDY DESIGN: This was a randomized, open label, prospective, controlled, parallel-group study involving 100 children (M/F: 38/62; mean age ± SD: 6.5 ± 2.7 years) who were diagnosed with CFC according to the Rome III Criteria. Children were randomly divided into 2 groups: 50 children received AFPFF (16.8 g daily) and 50 children received PEG+E (0.5 g/kg daily) for 8 weeks. Primary outcome measures were frequency of bowel movements, stool consistency, fecal incontinence, and improvement of other associated gastrointestinal symptoms. Safety was assessed with evaluation of clinical adverse effects and growth measurements. RESULTS: Compliance rates were 72% for AFPFF and 96% for PEG+E. A significant improvement of constipation was seen in both groups. After 8 weeks, 77.8% of children treated with AFPFF and 83% of children treated with PEG+E had improved (P = .788). Neither PEG+E nor AFPFF caused any clinically significant side effects during the entire course of the study period. CONCLUSIONS: In this randomized study, we did not find any significant difference between the efficacy of AFPFF and PEG+E in the treatment of children with CFC. Both medications were proved to be safe for CFC treatment, but PEG+E was better accepted by children. Copyright © 2012 Mosby, Inc. All rights reserved. DOI: 10.1016/j.jpeds.2012.04.043 PMID: 22677568 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.